Safety Study of GRNOPC1 in Spinal Cord Injury

Completed · Phase 1

Conditions studied: Spinal Cord Injury

In brief

The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).

Key facts

Study ID

NCT01217008

Run by

Lineage Cell Therapeutics, Inc.

People needed

5

Starts

2010-10-01

Expected to finish

2013-07-01

Last updated by the study team

2020-06-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Stanford University/Santa Clara Valley Medical Center — Palo Alto/San Jose, California, United States
• Shepherd Center — Atlanta, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• University of Maryland Medical Center/Kernan Orthopaedics and Rehabilitation Hospital — Baltimore, Maryland, United States
• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States
• The Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.